Economists: U.S. May ADP private sector employment is expected to be similar to April's data

金十2026/06/03 07:17

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

```htmlGolden Ten Data reported on June 3 that Dave Sloan, Senior Economist at Continuum Economics, expects the US May ADP private sector employment to increase by around 100 thousand, roughly in line with the April increase of 109 thousand. The April growth was the strongest performance since January 2025. However, he pointed out that this estimate is still below the implied momentum from the ADP weekly employment reports for the week ending May 9. Based on an average of 37,750 jobs added per week over the past four weeks, the corresponding monthly increase should be stronger. He added that it is noteworthy that the trend in ADP weekly employment data released in early April is quite similar to the performance in early May. Therefore, from historical experience, the May ADP employment increase may still remain close to the level seen in April.```

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Latest Update October 8 – Pacira BioSciences (PCRX.O) shares surged by 44%, hitting a more than three-year high at $36.30. If the rally holds, PCRX is poised for its largest single-day gain on record. Pharmaceutical company Viatris (VTRS.O) will acquire Pacira BioSciences in a $1.65 billion cash deal, offering $36.50 per share. The offer represents a premium of approximately 44.8% over Pacira’s recent closing price of $25.20. The transaction will add Pacira’s non-opioid pain medications Exparel and Zilretta to Viatris' product portfolio. Viatris shares fell 2.6% to $17.04. JPMorgan stated: “We believe this acquisition will not significantly alter VTRS' overall financial profile in the short or long term, and expect Exparel’s sales to gradually decline post-2030 due to generic market entry.” Both parties expect to complete the transaction by the end of 2026. Including intraday fluctuations, PCRX shares have risen 40.2% year-to-date, while VTRS has gained 36.8%. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. As automated translation may contain errors or lack the necessary context, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters assumes no liability for any damage or losses resulting from the use of automated translation.)

路透社•2026/10/08 16:11